Table 73.1DNA vaccination approaches for herpes viruses

Advantages Disadvantages
[bullet] Manufacture process and analytical testing are the same across different constructs [bullet] Suboptimal responses in human trials to date
[bullet] Stability [bullet] Regulatory pathway influenced by gene therapy
[bullet] Time to clinic [bullet] Population fear of “genetic” immunization
[bullet] Safety [bullet] Not yet manufactured to scale
[bullet] Ability to titrate immune response to humoral or T-cell arms based on formulations/adjuvants [bullet] Possible need for more than a single injection to induce responses in humans
[bullet] Ease of multivalent approaches
[bullet] Ability to modify or detoxify the genes of interest
[bullet] Lack of prior immunity or immune responses to the plasmid backbone

From: Chapter 73, DNA vaccines for human herpesviruses

Cover of Human Herpesviruses
Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.
Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors.
Cambridge: Cambridge University Press; 2007.
Copyright © Cambridge University Press 2007.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.